EMTN Prospectus

RNS Number : 2310Y

GlaxoSmithKline PLC

11 May 2021

 

Publication of Base Prospectus

The following base prospectus dated 10 May 2021 has been approved by the Financial Conduct Authority and is available for viewing:

GlaxoSmithKline plc, GlaxoSmithKline Capital plc, GSK Capital B.V. and GSK Capital K.K. £20,000,000,000 Euro Medium Term Note Programme

Copies of the base prospectus and the documents incorporated by reference within it have been submitted to the UK Listing Authority's NSM submission portal via the Electronic Submission System (ESS). The base prospectus will shortly be available for inspection at and can be downloaded from:

https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

For further information, please contact:

GlaxoSmithKline plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom

Enquiries:

UK Media enquiries:	Mary Hinks-Edwards David Mawdsley Simon Steel	[phone] [phone] [phone]
European Analyst/Investor enquiries:	James Dodwell Danielle Smith	[phone] [phone]

BASIS ON WHICH YOU MAY ACCESS THE BASE PROSPECTUS

Please note that the information contained in the base prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the base prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom the offer contained in the base prospectus is not addressed. Prior to relying on the information contained in the base prospectus you must ascertain from the base p rospectus whether or not you are part of the intended addressees of the information contained therein.

Your right to access this service is conditional upon complying with the above requirements.

 

END

 

 

PDIKFLBFFELXBBD